Filing summary
Entity and period: The filing is for Reinvent Technology Partners Z, a SPAC, for the three months ended March 31, 2021. Although the request identifies Hippo Holdings Inc., this is not Hippo’s operating-company 10-Q; it reports the SPAC before its proposed merger with Hippo Enterprises Inc. The SPAC had no operating revenue or business operations.
Financial results and position
| Metric | Q1 2021 / March 31, 2021 |
|---|---|
| Revenue | None; the SPAC expected no operating revenue before a business combination. |
| General and administrative expense | $1.46 million |
| Net loss | $2.46 million, including a $1.06 million noncash loss from increased warrant-liability fair value, partly offset by $52,917 of trust investment gains. |
| Margins and EPS | Not meaningful for a pre-combination SPAC. Basic and diluted loss per Class B share was $0.43; the Class A amount is shown as zero/ dash. |
| Operating cash flow | $(408,970); cash declined from $622,985 to $214,015. |
| Assets and trust | Total assets were $231.22 million, including $230.07 million in the Trust Account. |
| Liabilities and equity | Total liabilities were $23.83 million, including $14.53 million of derivative warrant liabilities and $8.05 million of deferred underwriting commissions. Shareholders’ equity was $5.00 million; $202.39 million of Class A shares was classified as temporary equity due to redemption rights. |
| Debt and liquidity | No long-term debt or working-capital loans were outstanding. The filing states working capital of approximately $90,000 and management believed resources and potential sponsor borrowing capacity would meet needs through a combination or one year from filing. Sponsor/affiliate loans were optional, not committed. |
Changes, transaction, and outlook
- There is no comparable Q1 2020 operating period presented. Q1 activity related to SPAC formation, public-company expenses, and seeking a merger target.
- In February 2021, the SPAC agreed to combine with Hippo Enterprises Inc. The stated transaction value was $5.0 billion of enterprise value plus Hippo cash of $522 million as of December 31, 2020. Closing remained subject to conditions.
- A concurrent PIPE was subscribed for 55 million shares at $10 per share, or $550 million in aggregate, subject to closing conditions.
- The filing provides no operating forecast or earnings guidance. If no business combination is completed within the 24-month period after the November 2020 IPO, the deadline could extend to 27 months if specified agreement milestones are met; otherwise, public shares are to be redeemed and the SPAC liquidated.
Risks, contingencies, and unusual items
- Cash figure discrepancy: The balance sheet and cash-flow statement report March 31 cash of $214,015, while the liquidity discussion says approximately $623,000 in the operating bank account. The filing text does not reconcile these values; verify the correct available operating cash and working-capital calculation.
- The $1.06 million warrant remeasurement loss is noncash and depends on fair-value estimates; private warrants were valued using Level 3 inputs.
- Management concluded disclosure controls were ineffective because of a material weakness in warrant accounting. The filing links the weakness to a prior financial-statement restatement described in the May 11, 2021 Form 10-K/A. Management reported no material changes in internal control during this quarter.
- COVID-19 effects on the SPAC’s ability to complete a transaction and on financial markets were uncertain. The filing reports no material changes to previously disclosed risk factors.
- The SPAC had a $625,000 annual support-services arrangement with a sponsor affiliate. It recognized approximately $156,000 in Q1; related-party amounts and reimbursements are disclosed.
- The $8.05 million deferred underwriting commission is payable only if a business combination is completed; warrants may expire worthless if the SPAC liquidates.
Important facts for investors to verify
- Confirm the registrant and reporting scope: this filing is for Reinvent Technology Partners Z, not Hippo’s standalone operating results.
- Reconcile the reported $214,015 balance-sheet cash with the approximately $623,000 cited in the liquidity discussion.
- Review the Hippo merger agreement, PIPE funding conditions, redemption levels, and any subsequent closing or transaction updates.
- Assess remediation of the warrant-accounting material weakness and the effects of the prior restatement.
- Verify the SPAC’s remaining operating cash, related-party costs, and ability to fund expenses without relying on uncommitted sponsor loans.